MGC Pharmaceuticals Ltd outlines investment highlights at Proactive medicinal cannabis webinar

by Newsfeed


The company is developing medicines that leverage its proprietary medicinal cannabis formula through clinical trials in Israel and Australia, enabling future medical product sales across the globe.

() outlined its progress and investment highlights during Proactive’s medicinal cannabis webinar today.

Co-founder and MD Roby Zamer said the company was developing medicines that leveraged its proprietary medicinal cannabis formula through clinical trials in Israel and Australia, enabling future medical product sales across the globe following regulatory approvals.

Two cannabinoid medicinal products

The vertically integrated, European-based bio-pharma company has two investigational medicinal products targeting refectory epilepsy and dementia as well as Alzheimer’s disease.

These include CannEpil®, an oral…



Read Full Article Here